IL1B and gestational diabetes: Glibenclamide (previously used to treat GDM) [91] has demonstrated promising results by reducing IL‐1β levels in trophoblast [71] and caspase‐1 protein expression in the supernatants of placental cultures after exposure to oxidative stress [63]; however, its development is limited.